Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 3/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522641 | 0.85 | PTPN1 (0.41) | PTPN1HDAC1HDAC2 | |
| SCHEMBL29649478 | 0.81 | SSTR3 (0.44) | PTPN1CTSL | |
| SCHEMBL15669378 | 0.80 | HTR2A (0.40) | PTPN1TGM2 | |
| SCHEMBL15669247 | 0.77 | HTR2A (0.35) | PTPN1TGM2 | |
| SCHEMBL12475662 | 0.76 | MDM2 (0.48) | PTPN1CTSLTGM2 | |
| SCHEMBL12475679 | 0.76 | MDM2 (0.48) | PTPN1CTSLTGM2 | |
| SCHEMBL18683434 | 0.76 | MDM2 (0.42) | PTPN1CTSL | |
| SCHEMBL25361716 | 0.75 | PTPN1 (0.43) | PTPN1CTSLTGM2 | |
| SCHEMBL25361722 | 0.75 | PTPN1 (0.43) | PTPN1CTSLTGM2 | |
| SCHEMBL26015625 | 0.75 | SSTR3 (0.48) | PTPN1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281630-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | TORAY INDUSTRIES, INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| EP-4580754-A1 | AN INTEGRIN ALPHA10 ANTIBODY DRUG CONJUGATE | Targinta AB (SE) | 2025-07-09 | — | — | EP | disclosed |
| EP-4400121-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024047172-A1 | AN INTEGRIN ALPHA10 ANTIBODY DRUG CONJUGATE | TARGINTA AB (SE) | 2024-03-07 | — | — | WO | disclosed |
| US-20230398232-A1 | Composition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of Cancer | Navrogen, Inc. | 2023-12-14 | — | — | US | disclosed |
| EP-4217009-A1 | COMPOSITION AND USE OF ALTERNATIVELY FORMATTED ANTI-MESOTHELIN ANTIBODIES FOR THE TREATMENT OF CANCER | Navrogen, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116390733-A | Compositions and uses of alternative formatted anti-mesothelin antibodies for the treatment of cancer | 纳夫罗根公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023033129-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2023-03-09 | — | — | WO | disclosed |
| US-11459397-B2 | Self-crosslinking antibodies | Meditope Biosciences Inc. (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2022067224-A1 | COMPOSITION AND USE OF ALTERNATIVELY FORMATTED ANTI-MESOTHELIN ANTIBODIES FOR THE TREATMENT OF CANCER | Navrogen, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459397-B2 | Self-crosslinking antibodies | FCGR2A, CD47, FCGR3B | PTPN1 532/4885P2RX7 4617/4885CTSL 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.